Feedback PLC Licence of TexRAD to Stone Checker (3211A)
28 September 2015 - 8:01AM
UK Regulatory
TIDMFDBK
RNS Number : 3211A
Feedback PLC
28 September 2015
Feedback plc
("Feedback" or the "Company")
Intention to develop a product incorporating TexRAD for kidney
stones
Feedback plc (AIM: FDBK), the medical imaging software company,
previously announced on 13 April 2015 that it had signed a research
agreement with the Oxford Stone Group at the University of Oxford
& Oxford University Hospital NHS Trust ("Oxford"), UK to
investigate the potential future clinical application of Feedback's
TexRAD texture analysis software on computed tomography (CT) image
data of patients with kidney stones. On 11 May 2015, Feedback
announced the pilot results from a preliminary feasibility
study.
A larger retrospective validation study comprising 90 patients
carried out by the Oxford research team led by Mr Ben Turney
(Bernard Senior Clinical Researcher in Urology at the University of
Oxford and Honorary Consultant Urological Surgeon) is currently
under way.
Following these studies, Feedback is pleased to announce the
incorporation of a 50:50 joint venture company "Stone Checker
Software Ltd" ("Stone Checker") with U.K. Urology Associates
Limited (UKUA) to commercialise the specific application of TexRAD
texture analysis in Urolithiasis. To facilitate this, Feedback Plc
has granted a licence of TexRAD intellectual property to Stone
Checker.
UKUA has expertise in a wide range of technology applications in
the specialist Urology field. This knowledge extends from the
development and distribution of novel medical equipment for both
benign and malignant urological diseases through to the use of
software in urodynamics. The team comprises an experienced group of
healthcare technology innovators.
The vision of Stone Checker is to develop a composite risk
stratification software product following stringent clinical
standards and regulatory standards. TexRAD CT texture analysis will
be incorporated with other known clinical markers to develop an
integrated product which would potentially assist urologists and
radiologists to provide better patient management and treatment
decisions for improved patient outcomes. There is a large potential
worldwide market for a non-invasive risk stratification tool based
on the common occurrence of kidney stones around the world.
Mr Jeevan Virk, Chief Operations Officer of UKUA commented:
"The opportunity to collaborate with Feedback plc in the
development of a specific urological software is hugely exciting
and will provide enormous benefits to patients who will receive
appropriate therapy, clinicians who will be able to optimise their
use of time and improve success rates, and the healthcare payers
who will no longer have to pay for high failure rates in
lithotripsy. It is unusual to have a product which fully lines up
to provide benefits to the whole clinical team, but this is the
promise of Stone Checker software."
Dr. Balaji Ganeshan, Chief Scientist & New Business Officer
of the Company's subsidiaries TexRAD Ltd & Cambridge Computed
Imaging Ltd commented:
"We are delighted with the formation of a new JV company with
UKUA, Stone Checker Software Ltd, to develop a novel composite
clinical score based software product dedicated to the management
of kidney stone patients."
For further information contact:
Feedback plc Tel: 01954
718072
Simon Barrell / Trevor Brown
/ Tom Charlton
Sanlam Securities UK (Nominated Tel: 020 7628
Adviser and Joint Broker) 2200
Simon Clements / Virginia Bull
Peterhouse Corporate Finance Tel: 020 7469
Ltd (Joint Broker) 0936
Lucy Williams / Duncan Vasey
Notes to editors:
TexRAD is a novel sophisticated imaging risk stratification
research tool that analyses the textures in existing radiological
scans. This research software application analyses textures,
detecting and measuring tumour heterogeneity (complexity) from
these images, revealing more information from medical images than
is readily visible to the naked eye. Research to date has shown
that TexRAD could potentially assist the clinician (as an
'Imaging-Biomarker') in confident decision-making: it has the
potential to assess the prognosis, disease-severity (e.g. risk of
metastases) and response evaluation of patients with cancer.
Currently TexRAD research has shown great potential in many
different oncological sites, including, colorectal, breast, lung,
prostate, oesophageal, head & neck, lymphoma, liver and renal
cancers and could potentially be employed as a heterogeneity
assessing tool in the era of 'Precision and Personalized Medicine'.
TexRAD is manufactured under licence by company Cambridge Computed
Imaging Ltd, a subsidiary of Feedback plc. More information is
available on www.fbk.com and www.texrad.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDBGDCCXDBGUR
(END) Dow Jones Newswires
September 28, 2015 02:01 ET (06:01 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024